Zacks Investment Research on MSN

Masimo SET shows accurate pulse oximetry in newborns of all skin tones

Masimo MASI recently reported findings from the NeoPODS study, a large prospective real-world evaluation of its SET pulse oximetry technology in critically ill newborns. The study demonstrated less ...
Las Vegas Sun

Masimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World Study

Masimo (NASDAQ: MASI) today announced the findings of a study evaluating the accuracy of Masimo SET ® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical ...
Hosted on MSN

NeoPODS study finds Masimo SET accurate across skin tones

Masimo’s NeoPODS study in critically ill newborns found its SET pulse oximetry technology delivered consistent accuracy across all skin tones, with less than 1% bias. The findings address longstanding ...
MassDevice

Masimo reports positive findings for pulse oximetry in hospitalized newborns of all skin tones

Masimo (Nasdaq:MASI) today announced new study findings supporting the use of its SET pulse oximetry in critically ill neonates.
Seeking Alpha

In Feasibility Study for Large, Prospective, Real-World Trial, Masimo SET® Performed Accurately on Critically Ill Adult ICU Patients of All Skin Tones

The INSPIRE Trial Prospectively Assesses Pulse Oximeter Accuracy Using a Unique Real-world Study Design and in the Feasibility Study Showed No Clinically Significant Bias Between Patients with Light ...
Nasdaq

Masimo to Present in the Wells Fargo Healthcare Conference

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient ...